Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.

EMBO Mol Med. 2018 Oct 30. pii: e9172. doi: 10.15252/emmm.201809172. [Epub ahead of print]

2.

p95HER2-T cell bispecific antibody for breast cancer treatment.

Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaat1445. doi: 10.1126/scitranslmed.aat1445.

PMID:
30282693
3.

Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer.

Méndez O, Peg V, Salvans C, Pujals M, Fernández Y, Abasolo I, Pérez J, Matres A, Valeri M, Gregori J, Villarreal L, Schwartz S Jr, Ramon Y Cajal S, Tabernero J, Cortés J, Arribas J, Villanueva J.

Clin Cancer Res. 2018 Aug 22. doi: 10.1158/1078-0432.CCR-18-0517. [Epub ahead of print]

PMID:
30135148
4.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS.

Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041. eCollection 2018 Apr 17.

5.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2018 Apr 30. doi: 10.1093/annonc/mdx804. [Epub ahead of print] No abstract available.

PMID:
29718117
6.

RNA Analysis as a Tool to Determine Clinically Relevant Gene Fusions and Splice Variants.

Teixidó C, Giménez-Capitán A, Molina-Vila MÁ, Peg V, Karachaliou N, Rodríguez-Capote A, Castellví J, Rosell R.

Arch Pathol Lab Med. 2018 Apr;142(4):474-479. doi: 10.5858/arpa.2017-0134-RA.

PMID:
29565207
7.

Beyond molecular tumor heterogeneity: protein synthesis takes control.

Ramon Y Cajal S, Castellvi J, Hümmer S, Peg V, Pelletier J, Sonenberg N.

Oncogene. 2018 May;37(19):2490-2501. doi: 10.1038/s41388-018-0152-0. Epub 2018 Feb 21. Review.

8.

Intraoperative Ultrasound-Guided Excision of Axillary Clip in Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Therapy (ILINA Trial) : A New Tool to Guide the Excision of the Clipped Node After Neoadjuvant Treatment.

Siso C, de Torres J, Esgueva-Colmenarejo A, Espinosa-Bravo M, Rus N, Cordoba O, Rodriguez R, Peg V, Rubio IT.

Ann Surg Oncol. 2018 Mar;25(3):784-791. doi: 10.1245/s10434-017-6270-z. Epub 2017 Dec 1.

PMID:
29197044
9.

The ever-evolving role of pathologists in the management of breast cancer with neoadjuvant treatment: recommendations based on the Spanish clinical experience.

Burgués O, López-García MÁ, Pérez-Míes B, Santiago P, Vieites B, García JF, Peg V.

Clin Transl Oncol. 2018 Mar;20(3):382-391. doi: 10.1007/s12094-017-1725-z. Epub 2017 Aug 9.

PMID:
28795336
10.

Role of total tumour load of sentinel lymph node on survival in early breast cancer patients.

Peg V, Sansano I, Vieites B, Bernet L, Cano R, Córdoba A, Sancho M, Martín MD, Vilardell F, Cazorla A, Espinosa-Bravo M, Pérez-García JM, Cortés J, Rubio IT, Ramón Y Cajal S.

Breast. 2017 Jun;33:8-13. doi: 10.1016/j.breast.2017.02.011. Epub 2017 Feb 28.

11.

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

Cejalvo JM, Martínez de Dueñas E, Galván P, García-Recio S, Burgués Gasión O, Paré L, Antolín S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano Á, Muñoz M, Nucíforo P, Vidal M, Pérez RM, Chacón López-Muniz JI, Caballero R, Peg V, Carrasco E, Rojo F, Perou CM, Cortés J, Adamo V, Albanell J, Gomis RR, Lluch A, Prat A.

Cancer Res. 2017 May 1;77(9):2213-2221. doi: 10.1158/0008-5472.CAN-16-2717. Epub 2017 Mar 1.

12.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

13.

Intraoperative assessment of sentinel lymph node by one-step nucleic acid amplification in breast cancer patients after neoadjuvant treatment reduces the need for a second surgery for axillary lymph node dissection.

Espinosa-Bravo M, Navarro-Cecilia J, Ramos Boyero M, Diaz-Botero S, Dueñas Rodríguez B, Luque López C, Ramos Grande T, Ruano Perez R, Peg V, Rubio IT.

Breast. 2017 Feb;31:40-45. doi: 10.1016/j.breast.2016.10.002. Epub 2016 Nov 2.

PMID:
27810698
14.

Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.

Hergueta-Redondo M, Sarrio D, Molina-Crespo Á, Vicario R, Bernadó-Morales C, Martínez L, Rojo-Sebastián A, Serra-Musach J, Mota A, Martínez-Ramírez Á, Castilla MÁ, González-Martin A, Pernas S, Cano A, Cortes J, Nuciforo PG, Peg V, Palacios J, Pujana MÁ, Arribas J, Moreno-Bueno G.

Oncotarget. 2016 Aug 30;7(35):56295-56308. doi: 10.18632/oncotarget.10787.

15.

peIF4E as an independent prognostic factor and a potential therapeutic target in diffuse infiltrating astrocytomas.

Martínez-Sáez E, Peg V, Ortega-Aznar A, Martínez-Ricarte F, Camacho J, Hernández-Losa J, Ferreres Piñas JC, Ramón Y Cajal S.

Cancer Med. 2016 Sep;5(9):2501-12. doi: 10.1002/cam4.817. Epub 2016 Jul 20.

16.

Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response.

Diaz-Botero S, Espinosa-Bravo M, Gonçalves VR, Esgueva-Colmenarejo A, Peg V, Perez J, Cortes J, Rubio IT.

Ann Surg Oncol. 2016 Nov;23(12):3831-3837. Epub 2016 Jun 29.

PMID:
27357178
17.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.

De Mattos-Arruda L, Mayor R, Ng CK, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J.

Nat Commun. 2015 Nov 10;6:8839. doi: 10.1038/ncomms9839.

18.

Intraoperative Ultrasound-Guided Lumpectomy Versus Mammographic Wire Localization for Breast Cancer Patients After Neoadjuvant Treatment.

Rubio IT, Esgueva-Colmenarejo A, Espinosa-Bravo M, Salazar JP, Miranda I, Peg V.

Ann Surg Oncol. 2016 Jan;23(1):38-43. doi: 10.1245/s10434-015-4935-z. Epub 2015 Oct 29.

PMID:
26514120
19.

MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.

De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L.

Oncotarget. 2015 Nov 10;6(35):37269-80. doi: 10.18632/oncotarget.5495.

20.

High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy.

Nuciforo P, Thyparambil S, Aura C, Garrido-Castro A, Vilaro M, Peg V, Jimenez J, Vicario R, Cecchi F, Hoos W, Burrows J, Hembrough T, Ferreres JC, Perez-Garcia J, Arribas J, Cortes J, Scaltriti M.

Mol Oncol. 2016 Jan;10(1):138-147. doi: 10.1016/j.molonc.2015.09.002. Epub 2015 Sep 15.

21.

Disruption of the ribosomal P complex leads to stress-induced autophagy.

Artero-Castro A, Perez-Alea M, Feliciano A, Leal JA, Genestar M, Castellvi J, Peg V, Ramón Y Cajal S, Lleonart ME.

Autophagy. 2015;11(9):1499-519. doi: 10.1080/15548627.2015.1063764.

22.

Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay.

Prat A, Galván P, Jimenez B, Buckingham W, Jeiranian HA, Schaper C, Vidal M, Álvarez M, Díaz S, Ellis C, Nuciforo P, Ferree S, Ribelles N, Adamo B, Ramón Y Cajal S, Peg V, Alba E.

Clin Cancer Res. 2016 Feb 1;22(3):560-6. doi: 10.1158/1078-0432.CCR-15-0630. Epub 2015 Jul 7.

23.

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.

Vicario R, Peg V, Morancho B, Zacarias-Fluck M, Zhang J, Martínez-Barriocanal Á, Navarro Jiménez A, Aura C, Burgues O, Lluch A, Cortés J, Nuciforo P, Rubio IT, Marangoni E, Deeds J, Boehm M, Schlegel R, Tabernero J, Mosher R, Arribas J.

PLoS One. 2015 Jun 15;10(6):e0129876. doi: 10.1371/journal.pone.0129876. eCollection 2015.

24.

Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements.

Teixidó C, Karachaliou N, Peg V, Gimenez-Capitan A, Rosell R.

Transl Lung Cancer Res. 2014 Apr;3(2):70-4. doi: 10.3978/j.issn.2218-6751.2014.02.02. Review.

25.

Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast.

Vidal M, Peg V, Galván P, Tres A, Cortés J, Ramón y Cajal S, Rubio IT, Prat A.

Mol Oncol. 2015 Jun;9(6):1081-90. doi: 10.1016/j.molonc.2015.01.003. Epub 2015 Jan 31.

26.

ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity.

Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Cajal SR, Campo JM, Felip E, Tabernero J, Cortés J.

Sci Rep. 2015 Feb 11;5:8179. doi: 10.1038/srep08179. No abstract available.

27.

Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.

Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortés J, Baselga J, Perou CM, Prat A, Rubio IT, Arribas J.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju291. doi: 10.1093/jnci/dju291. Print 2014 Nov.

28.

Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients.

Rubio IT, Espinosa-Bravo M, Rodrigo M, Amparo Viguri Diaz M, Hardisson D, Sagasta A, Dueñas B, Peg V.

Breast Cancer Res Treat. 2014 Sep;147(2):371-80. doi: 10.1007/s10549-014-3108-2. Epub 2014 Aug 28.

PMID:
25164972
29.

The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets.

Ramon Y Cajal S, De Mattos-Arruda L, Sonenberg N, Cortes J, Peg V.

Clin Transl Oncol. 2014 Nov;16(11):937-41. doi: 10.1007/s12094-014-1203-9. Epub 2014 Jul 25. Review.

PMID:
25060567
30.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2014 Sep;25(9):1729-35. doi: 10.1093/annonc/mdu239. Epub 2014 Jul 9.

PMID:
25009010
31.

Detection of sentinel lymph node in breast cancer recurrence may change adjuvant treatment decision in patients with breast cancer recurrence and previous axillary surgery.

Cordoba O, Perez-Ceresuela F, Espinosa-Bravo M, Cortadellas T, Esgueva A, Rodriguez-Revuelto R, Peg V, Reyes V, Xercavins J, Rubio IT.

Breast. 2014 Aug;23(4):460-5. doi: 10.1016/j.breast.2014.03.007. Epub 2014 Apr 13.

PMID:
24726837
32.

Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity.

Prat A, Adamo B, Fan C, Peg V, Vidal M, Galván P, Vivancos A, Nuciforo P, Palmer HG, Dawood S, Rodón J, Ramon y Cajal S, Del Campo JM, Felip E, Tabernero J, Cortés J.

Sci Rep. 2013 Dec 18;3:3544. doi: 10.1038/srep03544. Erratum in: Sci Rep. 2015;5:8179. Ramony Cajal, Santiago [corrected to Ramon y Cajal, Santiago].

33.

Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: the role of massively parallel sequencing.

De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J, Reis-Filho JS.

Mol Oncol. 2014 Feb;8(1):150-8. doi: 10.1016/j.molonc.2013.10.006. Epub 2013 Oct 31.

34.

miR-125b acts as a tumor suppressor in breast tumorigenesis via its novel direct targets ENPEP, CK2-α, CCNJ, and MEGF9.

Feliciano A, Castellvi J, Artero-Castro A, Leal JA, Romagosa C, Hernández-Losa J, Peg V, Fabra A, Vidal F, Kondoh H, Ramón Y Cajal S, Lleonart ME.

PLoS One. 2013 Oct 3;8(10):e76247. doi: 10.1371/journal.pone.0076247. eCollection 2013.

35.

Lymphatic mapping could not be impaired in the presence of breast carcinoma and coexisting small lymphocytic lymphoma.

Arana S, Vasquez-Del-Aguila J, Espinosa-Bravo M, Peg V, Rubio IT.

Am J Case Rep. 2013 Aug 21;14:322-5. doi: 10.12659/AJCR.884000. eCollection 2013.

36.

Prediction of non-sentinel lymph node metastasis in early breast cancer by assessing total tumoral load in the sentinel lymph node by molecular assay.

Espinosa-Bravo M, Sansano I, Pérez-Hoyos S, Ramos M, Sancho M, Xercavins J, Rubio IT, Peg V.

Eur J Surg Oncol. 2013 Jul;39(7):766-73. doi: 10.1016/j.ejso.2013.03.011. Epub 2013 Apr 19.

PMID:
23607911
37.

Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients.

Peg V, Espinosa-Bravo M, Vieites B, Vilardell F, Antúnez JR, de Salas MS, Delgado-Sánchez JJ, Pinto W, Gozalbo F, Petit A, Sansano I, Del Mar Téllez M, Rubio IT.

Breast Cancer Res Treat. 2013 May;139(1):87-93. doi: 10.1007/s10549-013-2524-z. Epub 2013 Apr 11.

PMID:
23576079
38.

Dual regulation of Myc by Abl.

Sanchez-Arévalo Lobo VJ, Doni M, Verrecchia A, Sanulli S, Fagà G, Piontini A, Bianchi M, Conacci-Sorrell M, Mazzarol G, Peg V, Losa JH, Ronchi P, Ponzoni M, Eisenman RN, Doglioni C, Amati B.

Oncogene. 2013 Nov 7;32(45):5261-71. doi: 10.1038/onc.2012.621. Epub 2013 Jan 14.

39.

Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis.

Torrejón D, Oliveira M, Cortes J, Sanchez-Olle G, Gómez P, Bellet M, Saura C, Peg V, Rovira A, Di Cosimo S.

Breast. 2013 Feb;22(1):19-23. doi: 10.1016/j.breast.2012.10.009. Epub 2012 Nov 6.

PMID:
23137566
40.

A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.

Morancho B, Parra-Palau JL, Ibrahim YH, Bernadó Morales C, Peg V, Bech-Serra JJ, Pandiella A, Canals F, Baselga J, Rubio I, Arribas J.

Oncogene. 2013 Mar 14;32(11):1452-9. doi: 10.1038/onc.2012.152. Epub 2012 May 28.

PMID:
22641219
41.

USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma.

Eichhorn PJ, Rodón L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V, Prat A, Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J.

Nat Med. 2012 Feb 19;18(3):429-35. doi: 10.1038/nm.2619.

PMID:
22344298
42.

Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer.

Rubio IT, Cebrecos I, Peg V, Esgueva A, Mendoza C, Cortadellas T, Cordoba O, Espinosa-Bravo M, Xercavins J.

J Surg Oncol. 2012 Jul 1;106(1):89-93. doi: 10.1002/jso.23048. Epub 2012 Jan 18.

PMID:
22258666
43.

The effect of p-4E-BP1 and p-eIF4E on cell proliferation in a breast cancer model.

Pons B, Peg V, Vázquez-Sánchez MA, López-Vicente L, Argelaguet E, Coch L, Martínez A, Hernández-Losa J, Armengol G, Ramon Y Cajal S.

Int J Oncol. 2011 Nov;39(5):1337-45. doi: 10.3892/ijo.2011.1118. Epub 2011 Jul 8.

PMID:
21750861
44.

Breast metastasis from rhabdomyosarcoma of the nasal septum in a pregnant adult woman.

Merced C, Rubio IT, Rodríguez J, Peg V, Xercavins J.

Breast J. 2011 Jul-Aug;17(4):420-1. doi: 10.1111/j.1524-4741.2011.01092.x. Epub 2011 Jun 2. No abstract available.

PMID:
21631632
45.

A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.

Parra-Palau JL, Pedersen K, Peg V, Scaltriti M, Angelini PD, Escorihuela M, Mancilla S, Sánchez Pla A, Ramón Y Cajal S, Baselga J, Arribas J.

Cancer Res. 2010 Nov 1;70(21):8537-46. doi: 10.1158/0008-5472.CAN-10-1701. Epub 2010 Oct 26.

46.

Intraoperative assessment of sentinel lymph nodes after neoadjuvant chemotherapy in patients with breast cancer.

Rubio IT, Aznar F, Lirola J, Peg V, Xercavins J.

Ann Surg Oncol. 2010 Jan;17(1):235-9. doi: 10.1245/s10434-009-0695-y. Epub 2009 Sep 24.

PMID:
19777186
47.

Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis.

Castellvi J, Garcia A, Ruiz-Marcellan C, Hernández-Losa J, Peg V, Salcedo M, Gil-Moreno A, Ramon y Cajal S.

Hum Pathol. 2009 Oct;40(10):1418-26. doi: 10.1016/j.humpath.2008.12.019. Epub 2009 May 9.

PMID:
19428047
48.

Pathological findings in the complete trisomy 9 syndrome: three case reports and review of the literature.

Ferreres JC, Planas S, Martínez-Sáez EA, Vendrell T, Peg V, Salcedo MT, Ramón Y Cajal S, Torán N.

Pediatr Dev Pathol. 2008 Jan-Feb;11(1):23-9. doi: 10.2350/06-08-0143.1. Review.

PMID:
18237231
49.

[The glycemic response to a test breakfast of an enteral diet with fiber and a high starch content in diabetics treated with insulin and oral antidiabetics].

Sanz París A, Peg V, Gamboa RA, Playán Usón J, Acha Pérez FJ, Casamayor Peris L, Celaya Pérez S.

Nutr Hosp. 1993 Nov;8(8):465-70. Spanish.

PMID:
8280804
50.

[Paper chromatography determination of trace elements].

PEG V, PARELLADA L.

Clin Lab (Zaragoza). 1957 Apr;63(373):263-7. Spanish. No abstract available.

PMID:
13437424

Supplemental Content

Support Center